propafenone has been researched along with Anomalous Ventricular Excitation Syndrome in 42 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 9.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 9.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 9.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 9.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 9.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 9.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels." | 7.74 | Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome. ( Fragakis, N; Iliadis, I; Katsaris, G; Lambrou, A; Papanastasiou, S, 2007) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 7.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 7.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| " The remaining side effects, if present, were tolerated, and dosage dependent." | 5.27 | Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Borggrefe, M; Breithardt, G; Seipel, L; Wiebringhaus, E, 1984) |
| "To evaluate the electrophysiological effects of intravenous propafenone in the anterograde and retrograde effective refractory period of the accessory pathways (AP), in patients with Wolff-Parkinson-White syndrome." | 5.07 | [Acute effects of propafenone in patients with ventricular pre-excitation]. ( Cruz Filho, F; Fagundes, ML; Lorga, AM; Loyola, LH; Maia, IG; Pimenta, J, 1993) |
| "The effects of intravenous flecainide and propafenone (2 mg/kg) administered in random order were compared in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome. ( Camm, AJ; Katritsis, D; Nunain, SO, 1992) |
| "In 34 patients with a symptomatic accessory atrioventricular connection the reversible protective effect of orally administered flecainide (300 mg/day) and of propafenone (900 mg/day) in control of ventricular response during atrial fibrillation by exercise was assessed." | 5.07 | Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection. ( Auricchio, A, 1992) |
| "We compared the electrophysiological effects of intravenous propafenone and flecainide on accessory pathway conduction by a randomized crossover study in 16 patients with Wolff-Parkinson-White syndrome." | 5.07 | A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. ( Camm, AJ; Garratt, CJ; Gill, J; Linker, NJ; O'Nunain, S; Ward, DE, 1991) |
| "The effects of intravenous procainamide (n = 30) or propafenone (n = 25) were evaluated in 55 patients with acute atrial fibrillation and the Wolff-Parkinson-White syndrome." | 5.06 | Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. ( Boahene, KA; Fujimura, O; Klein, GJ; Sharma, AD; Yee, R, 1990) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 5.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| " Thirteen patients had sustained orthodromic supraventricular tachycardia induced during baseline study, and two patients needed isoproterenol to render it sustained." | 5.06 | Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. ( Campa, MA; Dubuc, M; Kus, T; Lambert, C; Rosengarten, M; Shenasa, M, 1989) |
| "The efficacy and safety of intravenous propafenone was studied in 10 patients with Wolff-Parkinson-White syndrome and in 2 patients with a concealed accessory pathway." | 5.06 | Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Antman, EM; Friedman, PL; Ludmer, PL; McGowan, NE, 1987) |
| "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels." | 3.74 | Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome. ( Fragakis, N; Iliadis, I; Katsaris, G; Lambrou, A; Papanastasiou, S, 2007) |
| " After 24-hour Holter ECG monitoring had revealed Wolff-Parkinson-White syndrome as cause of the PSVT, propafenone was administered (15 mg/kg daily) and has prevented further recurrence of the tachycardia." | 3.69 | [Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants]. ( Gessler, P; Haas, NA; König, SA; Pufahl, C; Teufel, M, 1994) |
| "We describe a case of dangerous acceleration of conduction through an accessory pathway produced by the Class IC agent propafenone during routine electrophysiological study of a patient with Wolff-Parkinson-White syndrome." | 3.68 | Acceleration of conduction within an accessory pathway with propafenone. ( Holt, P; Sowton, GE; Sulke, AN, 1990) |
| "A 46 year-old woman with Wolff-Parkinson-White syndrome (postero-septal accessory pathway), symptomatic for recurrent episodes of nonsustained paroxismal supraventricular tachycardia (PSVT), was empirically treated with propafenone (600 mg/day)." | 3.68 | Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia. ( Calvi, V; di Bona, G; Manzoli, U; Montenero, AS; Natale, A; Santarelli, P, 1990) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 3.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "Noninvasive stress and pharmacologic tests with procainamide and propafenone were studied as methods to identify patients with Wolff-Parkinson-White syndrome (WPW) who would otherwise be judged at risk of sudden death on the basis of electrophysiologic criteria: the shortest RR interval during induced atrial fibrillation less than or equal to 250 ms or accessory pathway anterograde effective refractory period less than or equal to 250 ms." | 3.67 | Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. ( Brusca, A; Gaita, F; Giustetto, C; Mangiardi, L; Riccardi, R, 1989) |
| "0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia." | 3.67 | Diprafenone for treatment of Wolff-Parkinson-White syndrome. ( Geiger, M; Kuck, KH; Kunze, KP; Schlüter, M, 1989) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| ") and oral propafenone were evaluated in 14 patients with Wolff-Parkinson-White syndrome and in 10 patients with atrioventricular (AV) nodal reentrant tachycardia." | 3.67 | Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. ( Lüderitz, B; Manz, M; Steinbeck, G, 1985) |
| " Little justification for the use of agents or dosing in children is available." | 2.40 | Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. ( Kuhn, RJ; Luedtke, SA; McCaffrey, FM, 1997) |
| "Among them 29 cases with SVT (including WPW syndrome in 11, paroxysmal AF or Af in 3) and the other two cases were studied for other reasons." | 1.28 | [Electrophysiologic effects of intravenous propafenone]. ( Song, YC; Sun, RL; Zhang, S, 1989) |
| "Thus propafenone can produce rate-dependent failure of ventricular capture which is associated with marked prolongation of refractoriness and QRS duration suggesting a marked use-dependent drug effect in selected patients." | 1.28 | Rate-dependent failure of ventricular capture in patients treated with oral propafenone. ( Almendral, J; Arenal, A; Delcan, JL; Josephson, ME; San Román, D; Soriano, J, 1992) |
| " The remaining side effects, if present, were tolerated, and dosage dependent." | 1.27 | Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. ( Borggrefe, M; Breithardt, G; Seipel, L; Wiebringhaus, E, 1984) |
| " The same holds true for general tolerance: in 2 cases drug administration is discontinued and 11 patients present neurologic and digestive troubles improving after lowering the dosage or increasing the fractionation." | 1.27 | [Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation]. ( Cosnay, P; Fauchier, JP; Kapusta, P; Moquet, B; Rouesnel, P; Vrancea, F, 1986) |
| "Propafenone was administered during electrophysiologic testing to determine its efficacy and safety for terminating and preventing reinduction of paroxysmal supraventricular reentrant tachycardia." | 1.27 | Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. ( Gersh, BJ; Hammill, SC; Holmes, DR; McLaran, CJ; Osborn, MJ; Wood, DL, 1987) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (42.86) | 18.7374 |
| 1990's | 20 (47.62) | 18.2507 |
| 2000's | 2 (4.76) | 29.6817 |
| 2010's | 2 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Rosa, F | 1 |
| Mancuso, P | 1 |
| Chiatto, M | 1 |
| Calvelli, A | 1 |
| De Donato, V | 1 |
| Mazza, S | 1 |
| Spadafora, G | 1 |
| Paech, C | 1 |
| Flosdorff, P | 1 |
| Gebauer, RA | 1 |
| Koshumbaeva, KM | 1 |
| Belokopit, IN | 1 |
| Makhanov, DI | 1 |
| Nugmanova, MN | 1 |
| Fragakis, N | 1 |
| Iliadis, I | 1 |
| Papanastasiou, S | 1 |
| Lambrou, A | 1 |
| Katsaris, G | 1 |
| Coumel, P | 1 |
| Leclercq, JF | 1 |
| Assayag, P | 1 |
| Furlanello, F | 2 |
| Vergara, G | 2 |
| Dal Forno, P | 2 |
| Disertori, M | 2 |
| Inama, G | 2 |
| Breithardt, G | 2 |
| Borggrefe, M | 2 |
| Wiebringhaus, E | 1 |
| Seipel, L | 1 |
| Neumann, G | 1 |
| Grube, E | 1 |
| Funke, H | 1 |
| Bettini, R | 1 |
| Stefenelli, C | 1 |
| Zuechi, S | 1 |
| Bösche, J | 1 |
| Mattern, R | 1 |
| Chen, X | 1 |
| Martinez-Rubio, A | 1 |
| Hief, C | 1 |
| Haverkamp, W | 1 |
| Hindricks, G | 1 |
| Marafioti, V | 1 |
| Carbonieri, E | 1 |
| Zardini, P | 1 |
| Haas, NA | 1 |
| Pufahl, C | 1 |
| König, SA | 1 |
| Gessler, P | 1 |
| Teufel, M | 1 |
| Auricchio, A | 2 |
| Auricchio, U | 1 |
| Chiariello, L | 1 |
| Maia, IG | 1 |
| Cruz Filho, F | 1 |
| Fagundes, ML | 1 |
| Loyola, LH | 1 |
| Pimenta, J | 1 |
| Lorga, AM | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Luedtke, SA | 1 |
| Kuhn, RJ | 1 |
| McCaffrey, FM | 1 |
| Gómez-Barrado, JJ | 1 |
| García-Rubira, JC | 1 |
| Turégano Albarrán, S | 1 |
| Pavón García, M | 1 |
| Hidalgo Urbano, R | 1 |
| Montes Ramírez, JM | 1 |
| Cruz Fernández, JM | 1 |
| Manolis, AS | 1 |
| Katsaros, C | 1 |
| Cokkinos, DV | 1 |
| Camm, AJ | 2 |
| Katritsis, D | 1 |
| Nunain, SO | 1 |
| Soriano, J | 1 |
| Almendral, J | 1 |
| Arenal, A | 1 |
| San Román, D | 1 |
| Delcan, JL | 1 |
| Josephson, ME | 1 |
| O'Nunain, S | 1 |
| Garratt, CJ | 1 |
| Linker, NJ | 1 |
| Gill, J | 1 |
| Ward, DE | 1 |
| Goy, JJ | 1 |
| Fromer, M | 1 |
| Schlaepfer, J | 1 |
| Kappenberger, L | 1 |
| Santinelli, V | 2 |
| Turco, P | 2 |
| De Paola, M | 2 |
| Smimmo, D | 2 |
| Giasi, M | 1 |
| Santinelli, C | 1 |
| Chiariello, M | 2 |
| Condorelli, M | 2 |
| Wu, Z | 1 |
| Montenero, AS | 1 |
| Natale, A | 1 |
| di Bona, G | 1 |
| Calvi, V | 1 |
| Santarelli, P | 1 |
| Manzoli, U | 1 |
| Boahene, KA | 1 |
| Klein, GJ | 1 |
| Yee, R | 1 |
| Sharma, AD | 1 |
| Fujimura, O | 1 |
| Vassiliadis, I | 1 |
| Papoutsakis, P | 1 |
| Kallikazaros, I | 1 |
| Stefanadis, C | 1 |
| Sulke, AN | 1 |
| Holt, P | 1 |
| Sowton, GE | 1 |
| Kunze, KP | 1 |
| Schlüter, M | 1 |
| Geiger, M | 1 |
| Kuck, KH | 1 |
| Zhang, S | 1 |
| Sun, RL | 1 |
| Song, YC | 1 |
| Dubuc, M | 1 |
| Kus, T | 1 |
| Campa, MA | 1 |
| Lambert, C | 1 |
| Rosengarten, M | 1 |
| Shenasa, M | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Riccardi, R | 1 |
| Mangiardi, L | 1 |
| Brusca, A | 1 |
| Lacroix, H | 1 |
| Frank, R | 1 |
| Tonet, JL | 1 |
| Fontaine, G | 1 |
| Wajman, A | 1 |
| Squeir, S | 1 |
| Grosgogeat, Y | 1 |
| Barbieri, O | 1 |
| Cammalleri, G | 1 |
| Gruttadauria, G | 1 |
| Rugiano, A | 1 |
| Vancheri, F | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Moquet, B | 1 |
| Rouesnel, P | 1 |
| Kapusta, P | 1 |
| Vrancea, F | 1 |
| Ludmer, PL | 1 |
| McGowan, NE | 1 |
| Antman, EM | 1 |
| Friedman, PL | 1 |
| Hammill, SC | 1 |
| McLaran, CJ | 1 |
| Wood, DL | 1 |
| Osborn, MJ | 1 |
| Gersh, BJ | 1 |
| Holmes, DR | 1 |
| Manz, M | 2 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Lüderitz, B | 2 |
| Steinbeck, G | 1 |
3 reviews available for propafenone and Anomalous Ventricular Excitation Syndrome
| Article | Year |
|---|---|
[Ventricular preexcitation: is risk stratification feasible?].
Topics: Adolescent; Adult; Age Distribution; Ajmaline; Atrioventricular Node; Catheter Ablation; Child; Chil | 2010 |
[Progress in arrhythmology].
Topics: Adolescent; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Cardiac P | 1981 |
Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Child; Ch | 1997 |
10 trials available for propafenone and Anomalous Ventricular Excitation Syndrome
| Article | Year |
|---|---|
Efficacy of ajmaline and propafenone in patients with accessory pathways: a prospective randomized study.
Topics: Accessory Nerve; Adolescent; Adult; Aged; Ajmaline; Atrial Fibrillation; Electrophysiology; Female; | 1994 |
Partial reversal by exercise of protective effect in atrial fibrillation inducibility in patients with an accessory atrioventricular connection: comparison between flecainide and propafenone.
Topics: Adult; Arrhythmias, Cardiac; Electric Stimulation; Exercise Test; Female; Flecainide; Humans; Male; | 1994 |
[Acute effects of propafenone in patients with ventricular pre-excitation].
Topics: Adolescent; Adult; Atrioventricular Node; Electrocardiography; Female; Heart Block; Humans; Male; Mi | 1993 |
Effects of flecainide on atrial electrophysiology in the Wolff-Parkinson-White syndrome.
Topics: Atrial Fibrillation; Atrial Function; Cardiac Catheterization; Cardiac Pacing, Artificial; Flecainid | 1992 |
Reversible protective effect of propafenone or flecainide during atrial fibrillation in patients with an accessory atrioventricular connection.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Exercise; Exercise Te | 1992 |
A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Propafenon | 1991 |
Propafenone in Wolff-Parkinson-White syndrome at risk.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Fema | 1990 |
Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Echocardiography; Female; Humans; Male; Middle Aged; P | 1990 |
Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome.
Topics: Adult; Cardiac Pacing, Artificial; Clinical Trials as Topic; Double-Blind Method; Electrophysiology; | 1989 |
Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Topics: Adolescent; Adult; Atrial Fibrillation; Clinical Trials as Topic; Electrophysiology; Female; Follow- | 1987 |
29 other studies available for propafenone and Anomalous Ventricular Excitation Syndrome
| Article | Year |
|---|---|
Pharmacologic cardiac resynchronization of a 1-year-old boy with severe left ventricular dysfunction.
Topics: Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy; Echocardiography; Electrocardiography; Hu | 2012 |
[Preventive efficacy of propafenone, its effect on functional state of the heart during long-term treatment of patients with paroxysmal atrioventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Hea | 2006 |
Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.
Topics: Brugada Syndrome; Electrocardiography; Female; Humans; Lithium Compounds; Middle Aged; Propafenone; | 2007 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
[Clinical experience with propafenone in paroxysmal supraventricular reciprocating tachycardias].
Topics: Anti-Arrhythmia Agents; Drug Evaluation; Female; Heart Rate; Humans; Male; Propafenone; Propiophenon | 1984 |
Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Fe | 1984 |
[The value of antitachycardia pacemaker therapy in patients with Wolff-Parkinson-White syndrome].
Topics: Anti-Arrhythmia Agents; Bundle of His; Digitalis Glycosides; Disopyramide; Electrocardiography; Huma | 1983 |
[Fatal poisoning with the antiarrhythmic agent propafenon].
Topics: Adult; Anti-Arrhythmia Agents; Chromatography, Gas; Forensic Medicine; Humans; Male; Propafenone; Pr | 1980 |
Cases in electrocardiography.
Topics: Atrial Fibrillation; Electrocardiography; Female; Humans; Middle Aged; Propafenone; Tachycardia, Par | 1995 |
[Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants].
Topics: Adenosine Triphosphate; Digoxin; Drug Therapy, Combination; Echocardiography; Electrocardiography; E | 1994 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
[Circulatory arrest after combined intravenous drugs for the treatment of orthodromic circular tachycardia of Wolff-Parkinson-White syndrome].
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Therapy, Combination; Female; Heart Arrest; Humans; Middle | 1997 |
Electrophysiological and electropharmacological studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing.
Topics: Adrenergic beta-Antagonists; Adult; Cardiac Pacing, Artificial; Drug Therapy, Combination; Female; F | 1992 |
Rate-dependent failure of ventricular capture in patients treated with oral propafenone.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Electrocardiography; Heart Rate; Heart Ventr | 1992 |
Electrophysiologic effects of intravenous propafenone at rest, during isoproterenol infusion and during exercise in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrioventricular Node; Cardiac Catheterization; Electrocardiography; Electrophysi | 1991 |
[Clinical electrophysiologic study in paroxysmal reentry tachycardia treated by rhythnorma].
Topics: Electrophysiology; Female; Heart; Humans; Male; Propafenone; Tachycardia, Atrioventricular Nodal Ree | 1990 |
Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia.
Topics: Administration, Oral; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecainide; Follow-Up | 1990 |
Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Drug Administration Schedule; Echocardiography; Electrocardiography; Ele | 1990 |
Acceleration of conduction within an accessory pathway with propafenone.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1990 |
Diprafenone for treatment of Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Electric Stimulati | 1989 |
[Electrophysiologic effects of intravenous propafenone].
Topics: Adolescent; Adult; Electrocardiography; Electrophysiology; Female; Humans; Injections, Intravenous; | 1989 |
Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death.
Topics: Adolescent; Adult; Child; Death, Sudden; Exercise Test; Female; Humans; Male; Middle Aged; Procainam | 1989 |
[Effect of oral propafenon on accessory pathways of atrioventricular conduction].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Electrocardiography; Female; Heart C | 1985 |
[I.v. propafenone in supraventricular paroxysmal tachyarrhythmias in patients with Wolff-Parkinson-White syndrome. 2 clinical cases].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Infusions, Intravenous; Propafenone | 1988 |
[Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Humans; Injections, Intravenous; Mal | 1986 |
Wolff-Parkinson-White at risk and propafenone.
Topics: Administration, Oral; Adult; Female; Humans; Pregnancy; Propafenone; Wolff-Parkinson-White Syndrome | 1988 |
Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
Topics: Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Conduction System; Hemodynamics; | 1987 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |
Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Child; | 1985 |